Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Alzheimer abeta peptide binding polypeptide

a technology of alzheimer's disease and binding polypeptide, which is applied in the field of alzheimer's disease abeta peptide binding polypeptide, can solve the problems of no treatment that significantly alters the course of the disease or efficiently stops its development, and achieves the effects of improving the folding of fusion proteins, increasing expression, and increasing stability

Inactive Publication Date: 2018-03-01
AFFIBODY TECH AB
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a new molecule that can treat various forms of Alzheimer's disease by reducing the amount of harmful peptides in the body. This molecule can be used to treat whole blood, plasma, or serum. This new treatment is more efficient and targeted than current therapies.

Problems solved by technology

Despite tremendous research efforts during the last decades, there is currently no treatment that significantly alters the course of the disease or efficiently stops its development (Citron (2010) Nat Rev Drug Discov 9(5):387-398).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alzheimer abeta peptide binding polypeptide
  • Alzheimer abeta peptide binding polypeptide
  • Alzheimer abeta peptide binding polypeptide

Examples

Experimental program
Comparison scheme
Effect test

example 1

Design and Cloning of Affinity Maturation Libraries

Summary

[0238]This Example describes the design and cloning of two affinity maturation libraries, ZASlib and ZSYMlib, based on dimers of the previously identified first generation Aβ peptide binding polypeptide variant ZAβ3 (SEQ ID NO:111).

Materials and Methods

[0239]Two SlonoMax® head-to-tail dimer libraries of double-stranded DNA were purchased from Sloning BioTechnology GmbH (Pucheim, Germany). Library oligonucleotides encoded the truncated helix 1 plus helix 2 and 3 of the first Z variant unit and helix 1 and 2 of the second Z variant unit, making up the first and second moieties of the Aβ peptide binding polypeptides (asymmetric library: 5′-GCG GGT GGG GAG NNN NNN TAT NNN NNN AAC TTA AAC GCG NNN CAA CTG TGT GCC TTC ATC NNN AGT TTA GAA GAT GAO CCA AGC CAA NNN GCT AAC TTG TTG GCA GAA GCT AAA AAG CTA AAT GAT GCT CAG GCG CCG GCG AGC AGC AGC AGC GGG AGC AGC AGC AGC GGG CGC GCG AGT GCG GGT CGC GAG NNN GTT TAT TTA NNN AAC TTA AAC GCG NN...

example 2

Flow Cytometric Sorting of Affinity Maturation Libraries and Sequencing of Isolated Polypeptides

Summary

[0244]This Example describes the cloning of the affinity maturation libraries of Example 1 into a vector for staphylococcal display, and subsequent sorting and selection of Aβ peptide binding polypeptides by flow cytometry utilizing increased stringency conditions in each sorting cycle. Sequencing of isolated variants lead to the identification of 51 unique variants from the asymmetric library (SEQ ID NO:1-51) and 55 unique variants from the symmetric library (SEQ ID NO:52-106).

Materials and Methods

[0245]At least ten times the library size of either library was inoculated to tryptic soy broth supplemented with yeast extract (TSB+Y; Merck, Darmstadt, Germany) and 20 μg / ml chloramphenicol, and grown overnight at 37° C. and 150 rpm. The following day, cells were harvested by centrifugation (6000 rpm, 6 min, 4° C.) and washed in phosphate-buffered saline supplemented with 0.1% Pluronic...

example 3

On-Cell Screening for Aβ Binding

Summary

[0249]In this Example, the affinity of 37 isolated polypeptide variants for Aβ peptide was analyzed by flow cytometry.

Materials and Methods

[0250]37 clones (ABPP001, 005, 009, 013, 014, 016, 018, 020, 021, 025, 026, 028, 033, 035, 037, 040, 042, 048, 049 and 050, corresponding to SEQ ID NO:1, 5, 9, 13, 14, 16, 18, 20, 21, 25, 26, 28, 33, 35, 37, 40, 42, 48, 49 and 50, respectively; and ABPP053, 054, 059, 060, 061, 062, 070, 075, 078, 084, 089, 090, 095, 096, 097, 100 and 104, corresponding to SEQ ID NO:53, 54, 59, 60, 61, 62, 70, 75, 78, 84, 89, 90, 95, 96, 97, 100 and 104, respectively), each occurring more than once in the selection results of Example 2, were individually inoculated to TSB+Y with chloramphenicol (10 μg / ml) and grown overnight at 37° C. and 150 rpm. 106 overnight-cultured cells were pelleted by centrifugation and washed in PBSP before resuspension in 1 nM biotinylated Aβ1-40 (AnaSpec). After 45 min incubation at room temperatur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to View More

Abstract

The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid β (Aβ) peptides (in the following referred to as Aβ), comprising the amino acid sequence EX2X3YX5X6NLX9AX11QLCAX16IX18X19X20 ED. The present disclosure also relates to the use of such Aβ peptide binding polypeptides as therapeutic, prognostic and / or diagnostic agents.

Description

FIELD OF THE INVENTION[0001]The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid β (Aβ) peptide (in the following referred to as Aβ). The present disclosure also relates to the use of such Aβ peptide binding polypeptides as therapeutic, prognostic and / or diagnostic agents.BACKGROUND[0002]Many different diseases, such as Alzheimer's disease, type II diabetes, primary and secondary systemic amyloidosis, and familial amyloid polyneuropathy 1, have been recognized as belonging to the growing family of amyloid diseases. All amyloid diseases have in common the presence of extracellular protein aggregates that may or may not be fibrillar.[0003]Alzheimer's disease (AD) is the leading cause of dementia worldwide, with approximately 35 million people affected. Current treatments for Alzheimer's disease provide only modest symptomatic relief, and there is a great need for therapies that slow the course of the disease and prevent or delay th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/47
CPCC07K14/4711A61K38/00C07K2317/92A61P21/00A61P25/00A61P25/16A61P25/28A61P27/02A61P27/06A61P27/12A61P43/00A61P3/10
Inventor STAHL, STEFANLOFBLOM, JOHNLINDBERG, HANNAHARD, TORLEIF
Owner AFFIBODY TECH AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com